The exclusion of older adults, particularly those with complex and multiple chronic conditions, from randomized clinical trials (RCTs) has been well chronicled.1,2 Less well studied is how the preventive benefits seen in participants in RCTs translate to older individuals with multiple chronic health problems.
Helping to fill this gap, O’Hare and coauthors3 investigate whether the benefits of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in preventing progression to end-stage renal disease (ESRD) that are seen in younger populations would be similar for older adults. Using a simulation design, the authors provide evidence that the same relative benefit of ACEIs and ARBs seen in participants in RCTs do not provide the same absolute benefit in terms of less ESRD in older adults; this finding is important because the results from the participants in the RCTs inform current guidelines. For most of the older veterans in their study, more than 100 persons would need to be treated to prevent 1 case of ESRD. For many subgroups, the number needed to treat was greater than 1000, a sharp contrast to the range of 9 to 25 reported in the 4 trials highlighted in the article. These findings leave one wondering whether the poor translation of the effectiveness of ACEIs and ARBs from younger to older individuals is an isolated situation or whether we are unwittingly subjecting older adults to a wide array of preventive treatments that have no or marginal benefit or even impart unintended harm. The study by O’Hare et al supports the need to look at this question more systematically and calls into question the prevailing practice of assuming that results extrapolate from young to old and from healthier to sicker populations.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.